データなし
データなし
Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
散户“带头大哥”发神秘图片 游戏驿站(GME.US)等Meme股应声上涨
Ocugen CEO to Present at NobleCon20 – Noble Capital Markets' 20th Annual Emerging Growth Equity Conference
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies Including Stargardt Disease
Ocugen Reports Positive Data for OCU400, OCU410
データなし